| 1.29 0.24 (22.86%) | 02-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.77  |
1-year : | 3.78 |
| Resists | First : | 2.37 |
Second : | 3.24 |
| Pivot price | 1.61 |
|||
| Supports | First : | 0.97 |
Second : | 0.8 |
| MAs | MA(5) : | 1.27 |
MA(20) : | 1.68 |
| MA(100) : | 3.24 |
MA(250) : | 5.95 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 10.9 |
D(3) : | 6.1 |
| RSI | RSI(14): 31.3 |
|||
| 52-week | High : | 20.54 | Low : | 0.97 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CDIO ] has closed above bottom band by 20.6%. Bollinger Bands are 3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.39 - 1.4 | 1.4 - 1.41 |
| Low: | 0.95 - 0.96 | 0.96 - 0.97 |
| Close: | 1.27 - 1.29 | 1.29 - 1.31 |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Tue, 20 Jan 2026
Chicago med-tech firm Cardio Diagnostics expands AI heart disease test to India - The Business Journals
Fri, 09 Jan 2026
The Beat: Chicago med-tech firm goes global - The Business Journals
Wed, 07 Jan 2026
Cardio Diagnostics stock rises on strategic expansion into India - Investing.com
Wed, 07 Jan 2026
Cardio Diagnostics Expands Global Footprint; Set To Launch PrecisionCHD In India; Stock Surges - Nasdaq
Tue, 06 Jan 2026
AI heart tests come to a Minnesota YMCA in new community program - stocktitan.net
Wed, 03 Dec 2025
CMS sets final payment rate of $854 for Cardio Diagnostics tests - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.7e+006 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 2 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.15e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -59 % |
| Return on Assets (ttm) | 950.8 % |
| Return on Equity (ttm) | -61.6 % |
| Qtrly Rev. Growth | 15780 % |
| Gross Profit (p.s.) | -19.59 |
| Sales Per Share | -38.31 |
| EBITDA (p.s.) | 5460.2 |
| Qtrly Earnings Growth | -12 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.8 |
| Dividend | 0 |
| Forward Dividend | 133590 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|